Explore

Trendline Trendline
TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment

TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment

TiumBio's Tosposertib Shows Promising Results in Head and Neck Cancer Treatment
Trendline Trendline
Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting

Iterion Therapeutics Validates Tegavivint as Targeted Therapy for Advanced HCC at ASCO Meeting
Trendline Trendline
TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer

TiumBio Presents Promising Phase 2a Data for Tosposertib in Head and Neck Cancer
Trendline Trendline
Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026
Trendline Trendline
CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO Meeting

CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO Meeting

CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO Meeting
Trendline Trendline
Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026

Kelun-Biotech Unveils Promising Phase II Data for Lunbotinib in RET Fusion-Positive NSCLC at ASCO 2026
Trendline Trendline
Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer

Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer

Innovent Biologics Reports Promising Results for IBI363 in Immunotherapy-Resistant Lung Cancer
Trendline Trendline
CARsgen's Satri-cel Shows Long-term Benefits in Gastric Cancer Treatment

CARsgen's Satri-cel Shows Long-term Benefits in Gastric Cancer Treatment

CARsgen's Satri-cel Shows Long-term Benefits in Gastric Cancer Treatment
Trendline Trendline
Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment
Trendline Trendline
CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO 2026

CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO 2026

CARsgen Presents Long-term Results of Satri-cel Therapy for Gastric Cancer at ASCO 2026
Trendline Trendline
Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO
Trendline Trendline
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promising Results in Lung Cancer Study

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promising Results in Lung Cancer Study

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promising Results in Lung Cancer Study